Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact

Author:

Duarte Catiá12ORCID,Kvien Tore K34,Sexton Joe3,Santos Eduardo56ORCID,de Wit Maarten7,Gossec Laure89,da Silva Jose A P12

Affiliation:

1. Department of Rheumatology, Centro Hospitalar e Universitário de Coimbra

2. Coimbra Institute for Clinical and Biomedical Research, Faculty of Medicine, University of Coimbra , Coimbra, Portugal

3. Department of Rheumatology, Diakonhjemmet Hospital

4. Faculty of Medicine, University of Oslo , Oslo, Norway

5. Viseu Higher School of Health , Viseu

6. Health Sciences Research Unit: Nursing, Nursing School of Coimbra , Coimbra, Portugal

7. Patient Research Partner , Amsterdam, The Netherlands

8. Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM

9. Rheumatology Department, Pitié Salpêtrière Hospital, AP-HP , Paris, France

Abstract

Abstract Objectives The Patient Experienced Symptom State (PESS) is a single-question, patient-reported outcome that is validated to assess global disease impact in RA. This study addresses its sensitivity to change, and reliability. Methods Disease activity, disease impact in the seven domains of RA Impact of Disease (RAID) and PESS were assessed in patients with RA from the NOR-DMARD registry, at two visits, 6 months apart. The PESS over the last week was scored at five levels, from ‘very bad’ to ‘very good’. Disease impact and disease activity were compared between patients who improved, maintained or worsened PESS over time, through one-way analysis of variance, with post hoc Bonferroni correction. Correlations between changes in these parameters were assessed through Spearman’s correlation coefficient. Sensitivity to change was assessed by standardized response mean (SRM) between the two visits. Reliability was analysed through intraclass correlation coefficient (ICC) between the two visits in patients with stable disease activity and impact. Results In 353 patients [76.8% females, mean (s.d.) 9.9 (9.6) years disease duration], improvement in PESS level was associated with substantial improvements in mean impact in all domains as well as disease activity (P <0.02). PESS change was moderately to strongly correlated with RAID domains and disease activity (rho: 0.4–0.7). PESS was responsive to change (SRM: 0.65, 95% CI: 0.54, 0.76), particularly among RAID responders (SRM: 1.79, 95% CI: 1.54, 1.99). PESS was moderately reliable in patients with stable condition (ICC: 0.72, 95% CI: 0.52, 0.83). Conclusion PESS is valid, feasible, reliable and responsive, representing an opportunity to improve the assessment of disease impact with minimal questionnaire burden.

Funder

Abbvie

Bristol Myers Squibb

Union Chimique Belge Pharma

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3